Plain-English translation of NCT07566585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called BSB-2002, which is made from your own immune cells that have been modified in a laboratory to recognize and attack leukemia cells carrying a specific mutation. The medication is designed for patients with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. Researchers want to find the safest and most effective dose of this personalized therapy.
Many patients with relapsed or refractory acute myeloid leukemia have limited treatment options and poor outcomes. This medication represents a new approach—using your own cells as a targeted weapon against cancer—which may offer hope for patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo apheresis—a procedure where blood is drawn, your immune cells are separated out, and the rest of your blood is returned to you. These cells will be sent to a laboratory where they are genetically modified to recognize your leukemia. Once modified, the cells will be reinfused into you as a single treatment dose. The study will monitor your safety and how well the treatment works, with follow-up visits to track your response over time.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States